The results illustrated that AKI (HR = 7.298, 95% confidence interval [CI] = 4.018–13.255, P < 0.001), triglycerides (HR = 1.140, 95% CI [1.049–1.238], P = 0.002), baseline SCr (HR = 1.008, 95% CI [1.002–1.014], P = 0.012), hematuria (HR = 2.246, 95% CI [1.039–4.852], P = 0.040), and kidney PLA2R staining 4+ (HR = 2.473, 95% CI [1.363–4.486], P = 0.003) were independent risk factors for renal endpoint events in patients with aMN, whereas serum C3 (HR = 0.082, 95% CI [0.020–0.342], P < 0.001) was an independent protective factor (Table 4). This evidence concerns the gene C3 and adrenomyeloneuropathy.